MyFinsight
Home
Blog
About
Contact
exel: the balance sheet
Download
Download image
Prepaid expenses and
other current assets
$76,595K
(9.68%↑ Y/Y)
Inventory
$27,402K
(30.40%↑ Y/Y)
Trade receivables,
net
$309,725K
(14.84%↑ Y/Y)
Marketable securities
$612,235K
(-34.23%↓ Y/Y)
Cash and cash
equivalents
$376,300K
(45.66%↑ Y/Y)
Right-of-use assets and other
non-current assets
$255,989K
(-24.75%↓ Y/Y)
Goodwill
$63,684K
(0.00%↑ Y/Y)
Deferred tax assets, net
$418,582K
(16.64%↑ Y/Y)
Property and equipment,
net
$104,748K
(-15.81%↓ Y/Y)
Non-current marketable
securities
$578,287K
(10.48%↑ Y/Y)
Total current assets
$1,402,257K
(-9.52%↓ Y/Y)
Total assets
$2,823,547K
(-4.62%↓ Y/Y)
Total liabilities and
stockholders equity
$2,823,547K
(-4.62%↓ Y/Y)
Total stockholders
equity
$2,160,700K
(-5.04%↓ Y/Y)
Total liabilities
$662,847K
(-3.21%↓ Y/Y)
Accumulated deficit
-$106,061K
(-17.46%↓ Y/Y)
Accumulated other
comprehensive income (loss)
$3,565K
(-9.88%↓ Y/Y)
Additional
paid-in-capital
$2,262,928K
(-4.17%↓ Y/Y)
Other non-current
liabilities
$112,607K
(17.22%↑ Y/Y)
Non-current operating lease
liabilities
$176,463K
(-9.25%↓ Y/Y)
Total current
liabilities
$373,777K
(-5.22%↓ Y/Y)
Common stock, 0.001 par
value 400,000 shares...
$268K
(-6.29%↓ Y/Y)
Other current
liabilities
$104,622K
(9.30%↑ Y/Y)
Accrued collaboration
liabilities
$23,428K
(-21.98%↓ Y/Y)
Rebates and fees due to
customers
$58,234K
(-6.82%↓ Y/Y)
Accrued clinical trial
liabilities
$57,781K
(2.84%↑ Y/Y)
Accrued compensation
and benefits
$104,364K
(15.19%↑ Y/Y)
Accounts payable
$25,348K
(-57.26%↓ Y/Y)
Back
Back
Balance Sheet
source: myfinsight.com
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)